Anthony Butler
Anthony Butler
emerge entire exactly expect group half number performance positive second stellar until within
The entire drug group is not exactly having a stellar performance and may not until the second half of 2002 when we expect a number of positive catalysts, in the form of drug approvals, to emerge within the sector,
delivered goes leaves negative public rarely sorry taste
There's a rarely a day that goes by where there's not a negative story about a drug company. The only thing that's been delivered to the public is negative information, and it leaves the public with a sorry taste in its mouth.
business cash change clout consumer create flow health increased likely loss note operate shelf space thus
While Pfizer's cash flow would likely be impacted by the loss or change in structure, we note that a partnership with another consumer health business could create increased clout for shelf space and thus operate with new synergies.